18.01.2021 | ORIGINAL ARTICLE
Role of 18F-FDG PET/CT imaging in cardiac and pericardial masses
verfasst von:
Hongyan Yin, MD, Wujian Mao, MD, Hui Tan, PhD, Na Zhu, MD, Quan Wan, MD, Jing Shi, MD, PhD, Lin Qiu, MD, Yan Xiu, PhD, Rongkui Luo, MD, Haojun Yu, BS, Hongcheng Shi, PhD
Erschienen in:
Journal of Nuclear Cardiology
|
Ausgabe 3/2022
Einloggen, um Zugang zu erhalten
Abstract
Background
Considering the few reported cardiac masses, PET/CT in the imaging workup of cardiac masses is not well established. This retrospective study analyzed the role of 18F-FDG PET/CT imaging in cardiac/pericardial masses.
Methods and results
Fifty-nine patients with newly diagnosed cardiac/pericardial masses who underwent PET/CT and transthoracic echocardiography (TTE) were recruited. Echocardiographic and PET/CT characteristics were evaluated for predictive value in differentiating malignant and non-malignant lesions using histologic confirmation as the gold standard. The McNemar test was used to test the differences in sensitivity between PET/CT and TTE. 18F-FDG PET/CT had higher sensitivity in determining the malignancy of cardiac/pericardial masses compared to TTE (sensitivity, 96.6% vs 72.4%, P = .039). However, when pericardial masses were excluded from the analysis, the difference in sensitivity between the two was not statistically significant (sensitivity, 95.6% vs 78.3%, P = .219). 18F-FDG PET/CT identified two malignant pericardial masses missed on TTE, changed the diagnostic orientation of TTE in 15 patients, and found seven patients with extracardiac lesions in 29 malignant patients.
Conclusions
PET/CT was an effective additional image modality in patients with suspected malignant cardiac mass for further confirmation and to screen for potential metastasis.
